Bnp And Ntprobnp Market Research, 2031
The global bnp and ntprobnp market size was valued at $1.1 billion in 2021 and is projected to reach $3.4 billion by 2031, growing at a CAGR of 12.2% from 2022 to 2031. BNP (B-type natriuretic peptide) and NTproBNP (N-terminal pro-B-type natriuretic peptide) are the biomarkers secreted by cardiomyocytes in the heart in response to increased ventricular blood volume or pressure. Elevated levels of these peptides in the blood can indicate the presence of heart failure, and they are used as diagnostic markers for various cardiovascular conditions such as myocardial infarction, congestive heart failure (CHF), and others. In addition, BNP and NTproBNP levels can also be used to monitor disease progression and predict the risk of hospitalization in heart failure patients. BNP and NTproBNP testing is an important tool in the diagnosis and management of various cardiac diseases.
Market dynamics
Growth & innovations in the medical devices industry for the manufacturing of advanced diagnostic and biomarker testing, owing to a massive pool of health-conscious consumers, creates an opportunity for the BNP and NTproBNP market analysis. The rise in the prevalence of various cardiovascular diseases is the major key factor driving the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), about 805,000 people in the U.S. have a heart attack each year out of which, 605,000 experienced a first heart attack. The risk of heart attacks, strokes, and other cardiovascular disorders has increased as a result of rising cigarette use, unhealthy diet, use of tobacco, and inactivity among young people. Thus it is one of the main causes of the global burden of disease majorly in low and middle-income countries. Furthermore, the growing adoption of point-of-care assays, due to its advantages such as remote monitoring, reduced lengths of stay, increased patient satisfaction and user experience, simpler sample collection, and increased accuracy as compared to traditional laboratory tests and rise in demand for non-invasive diagnostic testing positively impact the market growth. Non-invasive diagnostic testing is being favored by doctors, owing to the advantages of high accuracy and precision, less pain, and fast diagnosis as compared with conventional methods. In addition, the rise in government initiatives to increase the availability of point-of-care testing, telemedicine, and key market players to focus on developing technologically advanced point-of-care-testing products for cardiovascular diseases further propels the market growth.
In addition, the growth of the BNP and NTproBNP market size is expected to be driven by the high potential in emerging markets, such as India and Japan due to the availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in the prevalence of heart-related diseases, and rise in awareness about BNP and NTproBNP biomarkers testing. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to the rise in demand for enhanced healthcare services and significant investments by the government to improve healthcare infrastructure. The demand for BNP and NTproBNP testing is not only limited to developed countries but is also being witnessed in developing countries, such as China, and India, which fuels the growth of the market. Factors such as a rise in the incidence of heart failure, an increase in the number of the geriatric population more susceptible to cardiovascular diseases, an increase in R&D investments in the discovery & development of novel biomarker-based testing, and a rise in awareness regarding early detection of diseases, further drive the growth of the market.
However, the stringent government regulations regarding biomarkers testing are the main hurdle limiting the growth of the BNP and NTproBNP market share. Government regulations increase the time required to launch a biomarker in the market, as a gap exists in understanding the working of the product by regulatory authorities and researchers. Government regulations may also include requirements for quality control and standardization of BNP and NT-proBNP tests. In addition, elevated levels of BNP and NTproBNP are caused by conditions other than heart failures, such as renal failure, pulmonary embolism, and sepsis. As a result, BNP and NTproBNP testing can sometimes produce false positive results is anticipated to limit the adoption of BNP and NTproBNP testing and negatively impact the market growth.
On the other hand, an increase in the number of patients diagnosed with coronary artery disease across the globe further drives market growth. For instance, according to the National Library of Medicine (NIH), in 2021, it was estimated that coronary artery disease represented 2.2% of the overall global burden of disease and 32.7% had cardiovascular diseases. Thus, an increase in the prevalence of cardiovascular disease among the population provides the opportunity to key market players to invest and commercialize the products.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The global BNP and NTproBNP market share experienced a decline in 2020 due to the global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain and delayed diagnostic testing using BNP and NTproBNP biomarkers. However, COVID-19 was itself potentially associated with myocardial injury, arrhythmia, and venous and arterial thrombosis. It is therefore essential that the diagnosis and management of cardiac disease was optimized, which eventually increases the use of point-of-care BNP and NT-proBNP testing.
Segmental Overview
The BNP and NTproBNP market is segmented on the basis of application, location of testing, and region. On the basis of application, the market is classified into myocardial infarction, congestive heart failure (CHF), acute coronary syndrome (ACS), and others. On the basis of the location of testing, the market is segmented into point-of-care testing and laboratory testing. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA)
By Application
The market is segmented into myocardial infarction, congestive heart failure (CHF), acute coronary syndrome (ACS), and others. The myocardial infarction segment dominated the global market in 2021, owing to a rise in the number of cases of myocardial infarction, and the adoption of early diagnosis for prompt treatment which can help prevent further damage to the heart and increase the chances of survival. For instance, according to National Center for Biotechnology Information (NCBI), in August 2022, about three million people suffer from acute myocardial infarction across the globe, annually. Furthermore, key players like BioMérieux SA, offers VIDAS NT-proBNP2 for acute heart failure diagnosis. It is widely used to monitor disease progression in patients under emergency conditions. Availability of such products is expected to drive the growth and demand of the BNP and NTproBNP market.
By Application
The myocardial infraction segment dominated the global market in 2021
By Location of Testing
BNP and NTproBNP industry is segregated into point-of-care testing and laboratory testing. The point-of-care testing segment dominated the global market in 2021. This is attributed to improved diagnosis and treatment of heart failure, increased patient convenience, better resource utilization, improved clinical decision-making, and growth in demand for cardiac biomarker testing through point-of-care testing. Cardiac biomarker testing-based devices, kits, assays, and analyzers are mostly used in point-of-care testing. For Instance, F. Hoffmann La Roche AG offers Elecsys cardiac NT-proBNP product which is widely used to monitor disease progression in patients. In addition, technological advancements, cost-effectiveness, and increased awareness about early diagnosis and new methods for cardiac disease diagnosis is anticipated to drive the growth of the point-of-care testing segment.
By Location Of Testing
The point-of-care testing segment dominated the global market in 2021
By Region
The BNP and NTproBNP industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific accounted for a major share of the BNP and NTproBNP market in 2021 and is expected to maintain its dominance during the forecast period, owing to the strong presence of several major players, such as Abbott PerkinElmer Inc., and Siemens AG, and technological advancement in diagnostic methods. In addition, the rise in the number of cardiovascular diseases in this region also contributes to the growth of the market. Moreover, high purchasing power and a rise in awareness about various biomarker-based diagnostic testing are expected to drive market growth. In addition, Asia-Pacific is expected to grow at the fastest rate during the BNP and NTprobnp Market Forecast period. This is attributed to rising healthcare expenditure and the growing adoption of novel diagnostic testing driving the growth of the market. Furthermore, the Asia-Pacific is the larger medical devices industry with the availability of raw materials in abundance, which can be easily accessed by manufacturers, this, in turn, drives the growth of the market. It offers profitable opportunities for key players operating in the BNP and NTproBNP market, thereby registering the fastest growth rate during the forecast period, owing to, an increase in disposable incomes, as well as the well-established presence of domestic companies in the region.
By Region
Asia-Pacific accounted for a major share of the BNP and NTproBNP market in 2021
COMPETITION ANALYSIS
Competitive analysis and profiles of the major players in the BNP and NTproBNP market, such as Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffman La Roche Ltd., Gentian Diagnostics ASA, PerkinElmer Inc., Quidel Corporation, Scripps Laboratories, and Siemens AG. are provided in this report. Major players have adopted patents as a key developmental strategy to improve the product portfolio of the BNP and NTproBNP markets.
Some examples of patents in the market
Gentian Diagnostics ASA granted a patent in the U.S. for NT-proBNP in December 2022. It is a big milestone toward the development of NT-proBNP.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the BNP and ntprobnp market analysis from 2021 to 2031 to identify the prevailing BNP and ntprobnp market opportunity.
- Market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the BNP and ntprobnp market growth and segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional as well as global BNP and ntprobnp market trends, key players, market segments, application areas, and market growth strategies.
Bnp And Ntprobnp Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 3.4 billion |
 Growth Rate | CAGR of 12.2% |
 Forecast period | 2021 - 2031 |
 Report Pages | 213 |
 By Application |
|
 By Location of Testing |
|
 By Region |
|
 Key Market Players | Abbott Laboratories, Quidel Corporation, Danaher Corporation, Bio-Rad Laboratories, Inc., Biomerieux SA, PerkinElmer Inc., F Hoffman La Roche Ltd., Siemens AG, Scripps Laboratories, Gentian Diagnostics ASA |
Analyst Review
The analyst’s review section provides various opinions on the global BNP and NTproBNP markets. In accordance with several interviews conducted, the BNP and NTproBNP market is expected to witness healthy growth with the rise in the prevalence of cardiovascular diseases and an increase in awareness about the benefits of early disease diagnosis. In addition, an increase in the number of geriatric populations suffering more susceptible to cardiovascular diseases leads to high adoption of BNP and NTproBNP biomarkers, which are expected to significantly boost the growth of the BNP and NTproBNP markets. However, the complexity of interpretation and limited specificity of BNP and NTproBNP restrain the market growth.
According to the perspective of leading companies the global BNP and NTproBNP Market is expected to exhibit high growth potential attributable to factors such as an increase in the development of more sensitive and specific assays and an increase in the use of BNP and NTproBNP in diagnosis and management of cardiovascular conditions.
Furthermore, Asia Pacific is expected to witness the highest growth, in terms of revenue, owing to an increase in the demand for BNP and NTproBNP biomarkers and an increase in the prevalence of various cardiovascular diseases such as myocardial infarction and congestive heart failure, the development of healthcare facilities, and rise in public–private investments in the healthcare sector which are expected to boost the demand for BNP and NTproBNP in this region.
One of the major upcoming trends being observed in Bnp And Ntprobnp Market is the rise in utilization of Point of Care Testing owing to its varied benefits to patients as well as healthcare professionals.
The myocardial infraction segment dominated the global market in 2021
Asia-Pacific accounted for a major share of the BNP and NTproBNP market in 2021
The global bnp and ntprobnp market was valued at $1.1 billion in 2021 and is projected to reach $3.4 billion by 2031, growing at a CAGR of 12.2% from 2022 to 2031.
Quidel Corporation, Abbott, Perkin Elmer, Bio Rad, BioMérieux SA, and F. Hoffman La. Roche are few major companies operating in the Bnp And Ntprobnp Market.
The stringent government regulations regarding biomarkers testing is the main hurdle limit the growth of the BNP and NTproBNP market
increase in the number of patients diagnosed with coronary artery disease across the globe coupled with the availability of novel cardic markers further drive the market growth
Yes, competitive landscape included in the Bnp And Ntprobnp Market
Loading Table Of Content...
Loading Research Methodology...
